Integrating AI and Causal Genetics to Prioritize Therapeutic Targets for Aging and Age-Related Diseases.

Geoffrey H D Leung¹, Jianjiu Chen¹, I Aylin Ergun², Evgeny Izumchenko³, Alex Aliper⁴, Feng Ren⁵, Frank W Pun¹, Alex Zhavoronkov^1,6

¹Insilico Medicine Hong Kong Ltd, Hong Kong Science and Technology Park, Hong Kong, China.

²Union College, Schenectady, NY 12308, USA.

³Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL 60637, USA.

⁴Insilico Medicine AI Ltd, Masdar, Abu Dhabi, United Arab Emirates.

⁵Insilico Medicine Shanghai Ltd, Shanghair, China.

⁶Insilico Medicine US Inc, 1000 Massachusetts Avenue, Suite 126, Cambridge, MA 02138, USA.

PubMed DOI

Abstract

Aging is increasingly viewed as a pathological process and a principal driver of diverse age-related diseases (ARDs). Framing aging as a disease offers an opportunity to identify therapeutic targets capable of modifying multiple chronic disorders simultaneously. Here, we developed an artificial intelligence (AI)-driven target discovery framework that integrates large-scale multi-omic datasets to p…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.